Today we are going to be talking about GlaxoSmithKline’s recent announcement about payments to physicians for marketing purposes. In December of 2013, GSK decided to no longer to pay physicians directly to do one of three activities:
• Speak on their behalf
• Attend conferences on their behalf
• Directly market products on their behalf
The Physician Payment Sunshine Act (PPSA) went into effect on August 1, 2013, and with it comes a few notable changes to CME. As part of our continued efforts in research and funder development within the CME industry, Global has taken the initiative in analyzing the complexities and ambiguity of the new guidelines.
On Friday August 6, 2010, Don E. Moore, JR conducted a Pfizer webinar discussing outcomes assessments. For detailed notes and information from the Pfizer webinar, please see below.
Webcast: Pfizer First Friday Webinar Series: Outcomes Assessment
Date: Friday, August 6, 2010
Presenter: Don E. Moore, Jr., Ph.D
On March 15, 2010, Global participated in the Novartis Oncology Office of Grants & Education (OGE) and Oncology Affairs & Patient Advocacy (OA&PA) Informational Webcast. The highlights from the webinar are listed below:
In today’s playing field of certified medical education (CME) there is constant scrutiny from government and media stakeholders who believe that there is inherent bias in CME activities funded by pharmaceutical and medical device companies. In order to combat perceived bias many have suggested that commercial support of CME be eliminated, however others believe that commercial support is the only way to ensure high quality education is available to all physicians, nurses, pharmacists and other healthcare professionals.